UCB SA (UCBJF)
USD 150.7
(-5.46%)
USD 150.7
(-5.46%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 343 Million EUR | -17.94% |
| 2022 | 418 Million EUR | -60.49% |
| 2021 | 1.05 Billion EUR | 44.54% |
| 2020 | 732 Million EUR | -7.58% |
| 2019 | 792 Million EUR | -1.0% |
| 2018 | 800 Million EUR | 6.24% |
| 2017 | 753 Million EUR | 44.81% |
| 2016 | 520 Million EUR | -16.53% |
| 2015 | 623 Million EUR | 198.09% |
| 2014 | 209 Million EUR | 30.63% |
| 2013 | 160 Million EUR | -35.74% |
| 2012 | 249 Million EUR | 4.62% |
| 2011 | 238 Million EUR | 131.07% |
| 2010 | 103 Million EUR | -79.92% |
| 2009 | 513 Million EUR | 1121.43% |
| 2008 | 42 Million EUR | -73.75% |
| 2007 | 160 Million EUR | -56.4% |
| 2006 | 367 Million EUR | -51.39% |
| 2005 | 755 Million EUR | 130.89% |
| 2004 | 327 Million EUR | -3.3% |
| 2003 | 338.14 Million EUR | 1.78% |
| 2002 | 332.22 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 104 Million EUR | 225.0% |
| 2024 Q2 | 104 Million EUR | 0.0% |
| 2023 Q3 | 16 Million EUR | -94.86% |
| 2023 Q1 | 155.5 Million EUR | 718.42% |
| 2023 FY | 343 Million EUR | -17.94% |
| 2023 Q4 | 32 Million EUR | 100.0% |
| 2023 Q2 | 311 Million EUR | 100.0% |
| 2022 Q4 | 19 Million EUR | 0.0% |
| 2022 Q2 | 399 Million EUR | 100.0% |
| 2022 Q1 | 199.5 Million EUR | -59.03% |
| 2022 FY | 418 Million EUR | -60.49% |
| 2021 FY | 1.05 Billion EUR | 44.54% |
| 2021 Q4 | 487 Million EUR | 99.59% |
| 2021 Q3 | 244 Million EUR | -57.27% |
| 2021 Q2 | 571 Million EUR | 101.41% |
| 2021 Q1 | 283.5 Million EUR | -23.17% |
| 2020 Q2 | 363 Million EUR | 100.0% |
| 2020 Q4 | 369 Million EUR | 100.0% |
| 2020 Q1 | 181.5 Million EUR | -52.36% |
| 2020 FY | 732 Million EUR | -7.58% |
| 2020 Q3 | 184.5 Million EUR | -49.17% |
| 2019 Q4 | 381 Million EUR | 0.0% |
| 2019 FY | 792 Million EUR | -1.0% |
| 2019 Q1 | 205 Million EUR | 0.0% |
| 2019 Q2 | 411 Million EUR | 100.49% |
| 2018 Q2 | 275 Million EUR | 0.0% |
| 2018 FY | 800 Million EUR | 6.24% |
| 2018 Q1 | 275 Million EUR | 70.81% |
| 2017 FY | 753 Million EUR | 44.81% |
| 2017 Q2 | 215 Million EUR | 0.0% |
| 2017 Q1 | 215 Million EUR | 83.76% |
| 2017 Q4 | 161 Million EUR | 0.0% |
| 2017 Q3 | 161 Million EUR | -25.12% |
| 2016 Q1 | 154.5 Million EUR | 1136.0% |
| 2016 FY | 520 Million EUR | -16.53% |
| 2016 Q3 | 117 Million EUR | -24.27% |
| 2016 Q4 | 117 Million EUR | 0.0% |
| 2016 Q2 | 154.5 Million EUR | 0.0% |
| 2015 Q4 | 12.5 Million EUR | 0.0% |
| 2015 Q1 | 119.5 Million EUR | 724.14% |
| 2015 Q2 | 119.5 Million EUR | 0.0% |
| 2015 Q3 | 12.5 Million EUR | -89.54% |
| 2015 FY | 623 Million EUR | 198.09% |
| 2014 Q1 | 43 Million EUR | 230.77% |
| 2014 Q3 | 14.5 Million EUR | -66.28% |
| 2014 Q2 | 43 Million EUR | 0.0% |
| 2014 Q4 | 14.5 Million EUR | 0.0% |
| 2014 FY | 209 Million EUR | 30.63% |
| 2013 Q3 | 13 Million EUR | -53.57% |
| 2013 Q1 | 28 Million EUR | 0.0% |
| 2013 FY | 160 Million EUR | -35.74% |
| 2013 Q4 | 13 Million EUR | 0.0% |
| 2013 Q2 | 28 Million EUR | 0.0% |
| 2012 FY | 249 Million EUR | 4.62% |
| 2011 FY | 238 Million EUR | 131.07% |
| 2010 FY | 103 Million EUR | -79.92% |
| 2009 FY | 513 Million EUR | 1121.43% |
| 2008 FY | 42 Million EUR | -73.75% |
| 2007 FY | 160 Million EUR | -56.4% |
| 2006 FY | 367 Million EUR | -51.39% |
| 2005 FY | 755 Million EUR | 130.89% |
| 2004 FY | 327 Million EUR | -3.3% |
| 2003 FY | 338.14 Million EUR | 1.78% |
| 2002 FY | 332.22 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Qrons Inc. | -789.34 Thousand USD | 43553.64% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 647.932% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 9081.409% |
| Adynxx, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | -426.615% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 82655.316% |
| BioStem Technologies, Inc. | -8.48 Million USD | 4143.389% |
| Evofem Biosciences, Inc. | 52.97 Million USD | -547.426% |
| Skye Bioscience, Inc. | -37.64 Million USD | 1011.149% |
| Rebus Holdings, Inc. | -1.02 Million USD | 33727.451% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 5012.044% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | 25784.592% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 54337.224% |
| Nascent Biotech, Inc. | -2.08 Million USD | 16529.705% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 2261.114% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 557.559% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 5315.849% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | 125556.288% |
| SQZ Biotechnologies Company | -79.46 Million USD | 531.642% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 11958.689% |
| Propanc Biopharma, Inc. | -1.82 Million USD | 18940.688% |
| Mesoblast Limited | -87.95 Million USD | 489.968% |
| Marizyme, Inc. | -65.34 Million USD | 624.891% |
| Genus plc | 7.9 Million USD | -4241.772% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 3249.175% |
| Pharming Group N.V. | -10.54 Million USD | 3351.801% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 15907.807% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 9344.7% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 3978.336% |
| ContraFect Corporation | -65.15 Million USD | 626.453% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 7119.967% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | 19955.799% |
| IMV Inc. | -36.48 Million USD | 1040.094% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 4355.751% |
| MultiCell Technologies, Inc. | -380.07 USD | 90246633.533% |
| ONE Bio Corp. | 8.67 Million USD | -3853.156% |
| Accustem Sciences Inc. | -3.74 Million USD | 9255.409% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 763.546% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | 27168.96% |
| Q BioMed Inc. | -2.05 Million USD | 16814.642% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 9288.32% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 14506.498% |
| Biomind Labs Inc. | -1.21 Million USD | 28346.285% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 674.295% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 11158.209% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 4440.073% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | 17696.521% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | 2290431.197% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 5996.254% |
| GB Sciences, Inc. | -1.36 Million USD | 25289.527% |
| Alpha Cognition Inc. | -13.77 Million USD | 2590.458% |
| HST Global, Inc. | -146.21 Thousand USD | 234694.077% |
| CSL Limited | 2.64 Billion USD | 87.017% |
| Wesana Health Holdings Inc. | -1.75 Million USD | 19646.71% |
| Halberd Corporation | -79.67 Thousand USD | 430593.499% |
| Enzolytics Inc. | -2.17 Million USD | 15856.843% |
| Agentix Corp. | -1.37 Million USD | 25059.777% |
| Resverlogix Corp. | -3.61 Million USD | 9601.385% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 10915.29% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -295.05 Million USD | 216.25% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | -349900.0% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | -4853.359% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 8733.29% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 11434.59% |
| AVAX Technologies, Inc. | -6.41 Million USD | 5447.97% |
| Zenith Capital Corp. | -10.59 Million USD | 3337.071% |
| Genscript Biotech Corporation | -95.47 Million USD | 459.249% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | 1475876.611% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 8373.162% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | 567599.236% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 17206.251% |
| Kadimastem Ltd | -3.3 Million USD | 10470.69% |
| Helix BioMedix, Inc. | -1.05 Million USD | 32579.307% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | 77812.753% |
| LadRx Corporation | 400.44 Thousand USD | -85555.137% |
| Cell Source, Inc. | -5.32 Million USD | 6545.9% |
| Regen BioPharma, Inc. | 1.02 Million USD | -33412.195% |
| Regen BioPharma, Inc. | 1.02 Million USD | -33412.195% |
| NovAccess Global Inc. | -4.76 Million USD | 7292.001% |
| Affymax, Inc. | -14.42 Million USD | 2477.981% |
| Itoco Inc. | -1.86 Million USD | 18452.109% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 7820.817% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | 20651.228% |
| Mobile Lads Corp. | -2.26 Million USD | 15254.916% |
| CytoDyn Inc. | -49.84 Million USD | 788.188% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | 434095.926% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | 150454.846% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | 36530.105% |
| SYBLEU INC | -180.3 Thousand USD | 190334.271% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | 21368.192% |
| International Stem Cell Corporation | -131 Thousand USD | 261932.061% |
| Bioxytran, Inc. | -4.28 Million USD | 8114.015% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | 632101.769% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 13655.989% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 813.513% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 16325.166% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -780.88 Thousand USD | 44024.409% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 10927.02% |
| Neutra Corp. | -233.46 Thousand USD | 147017.097% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 1790.405% |
| PureTech Health plc | -65.69 Million USD | 622.094% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 1712.862% |
| IXICO plc | -1.17 Million USD | 29217.148% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 3555.223% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 700.406% |
| CSL Limited | 2.64 Billion USD | 87.017% |
| Cellectis S.A. | -103.17 Million USD | 432.449% |